<SEC-DOCUMENT>0001372514-24-000054.txt : 20240510
<SEC-HEADER>0001372514-24-000054.hdr.sgml : 20240510
<ACCEPTANCE-DATETIME>20240510070140
ACCESSION NUMBER:		0001372514-24-000054
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240510
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240510
DATE AS OF CHANGE:		20240510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KIORA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001372514
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36672
		FILM NUMBER:		24932839

	BUSINESS ADDRESS:	
		STREET 1:		332 ENCINITAS BOULEVARD
		STREET 2:		SUITE 102
		CITY:			ENCINITAS
		STATE:			CA
		ZIP:			92024
		BUSINESS PHONE:		781-788-8869

	MAIL ADDRESS:	
		STREET 1:		332 ENCINITAS BOULEVARD
		STREET 2:		SUITE 102
		CITY:			ENCINITAS
		STATE:			CA
		ZIP:			92024

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EYEGATE PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20060811
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>kprx-20240510.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3652cabc-38b6-450f-a909-c9466ceb4b5c,g:bc80bc13-a467-4786-8c57-b0dd8a605c36,d:d6d4fa0be171446590a2a80f9bfed2f3-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>kprx-20240510</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001372514</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="kprx-20240510.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-10</xbrli:startDate><xbrli:endDate>2024-05-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id6d4fa0be171446590a2a80f9bfed2f3_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-top:8pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CURRENT REPORT PURSUANT</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">TO SECTION 13 OR 15(d) OF THE</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported): </span><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">May 10, 2024</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">KIORA PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(State or other jurisdiction of incorporation)</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36672</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">98-0443284</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">332 Encinitas Blvd.</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 102</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Encinitas</ix:nonNumeric>,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-10">CA</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">92024</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">858</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">224-9600</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, $0.01 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">KPRX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" id="f-20">NASDAQ</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-21">&#9744;</ix:nonNumeric> </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id6d4fa0be171446590a2a80f9bfed2f3_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 2.02.&#160;&#160;&#160;&#160;Results of Operations and Financial Conditions.</span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On May 10, 2024, Kiora Pharmaceuticals, Inc. (the &#8220;Company&#8221;) issued a press release announcing financial results for the quarter ended March 31, 2024 and an update on clinical development progress. A copy of the release is attached as Exhibit 99.1.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information furnished pursuant to this Item 2.02, including Exhibit 99.1, is not deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. This information will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates them by reference. </span></div><div style="text-align:justify"><span><br/></span></div><div id="id6d4fa0be171446590a2a80f9bfed2f3_10"></div><div style="-sec-extract:summary;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:10pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</span><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.74pt"> Exhibits.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit&#160;<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex991-pressreleasemarch312.htm">99.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex991-pressreleasemarch312.htm">Press Release of Kiora Pharmaceuticals, Inc., dated as of May 10, 2024</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish copies of any of the omitted schedules and exhibits upon request by the U.S. Securities and Exchange Commission.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="id6d4fa0be171446590a2a80f9bfed2f3_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.841%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">KIORA PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Melissa Tosca</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Melissa Tosca</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President of Finance</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal financial and accounting officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 10, 2024</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991-pressreleasemarch312.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i5b6fb9a4f2d94338a3cf614aec689634_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Kiora Pharmaceuticals Reports First Quarter Results&#59; Update on Pipeline of Drugs Targeting Retinal Disease</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Phase 2 trial for KIO-301 for the treatment of retinitis pigmentosa, in partnership with Th&#233;a Open Innovation, expected to be initiated in Q4 2024</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Phase 2 clinical trial for KIO-104 for retinal inflammation expected to begin in 2025 </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Ended Q1 2024 with $31.3 million in cash and cash equivalents, providing an expected runway of more than two years</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Encinitas, California&#8212;May 10, 2024 - </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Kiora Pharmaceuticals, Inc. </font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(NASDAQ&#58; KPRX) (&#34;Kiora&#34; or the &#34;Company&#34;) announces first quarter 2024 financial results and updates on its development pipeline of treatments for retinal disease.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;Our balance sheet and strategic partnership with Th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#233;</font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a Open Innovation (TOI) put us in a strong position to advance our two retinal programs, KIO-301 and KIO-104, into mid-stage clinical trials,&#8221; said Brian M. Strem, Ph.D., chief executive officer of Kiora. &#8220;Both compounds, given their mechanisms of action, have the potential to address multiple diseases&#59; KIO-301 for the treatment of inherited retinal disorders, and KIO-104 for the treatment of retinal inflammatory diseases. Our upcoming Phase 2 ABACUS-2 trial of KIO-301 for the treatment of retinitis pigmentosa, is a multi-center double-masked, randomized, controlled, multiple-dose study performed in collaboration with TOI. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;As part of our partnership, TOI will fund the remaining clinical development of KIO-301 across multiple indications, allowing us to efficiently invest our capital in the development of KIO-104 to treat retinal inflammatory diseases. KIO-104 may address the established need for eye treatments that spare the complications of chronic steroid use and&#47;or systemic anti-inflammatory drugs. Clinical proof-of-concept for KIO-104 in the treatment of non-infectious uveitis, a rare retinal inflammatory condition, has been established with recently published results from </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a Phase 1&#47;2a study</font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Prior to initiating a Phase 2 trial, we are conducting additional investigational new drug (IND) enabling work. Beyond non-infectious uveitis, the mechanism of action of KIO-104 could apply to other retinal conditions, such as macular edema, and proliferative vitreoretinopathy (PVR), a serious complication following retinal detachment repair.&#8221; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><img alt="businesshighlightsa.jpg" src="businesshighlightsa.jpg" style="height:303px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#34;In the first quarter, we executed a strategic partnership with TOI, which included a $16 million upfront payment, and raised $15 million from an equity offering,&#34; added Melissa Tosca, EVP Finance. &#34;These developments substantially strengthened our cash position, allowing us to advance our two exciting programs while maintaining G&#38;A expenses, and provides a runway of greater than two years. The TOI upfront payment was </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">recognized entirely in the first quarter as collaboration revenue and we expect future development and regulatory milestone payments to be treated similarly.&#34;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Milestones achieved in the first quarter and year-to-date 2024 include the following&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">KIO-301</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Entered a strategic partnership granting TOI exclusive worldwide co-development and commercialization rights, excluding Asia, to KIO-301 for the treatment of retinal degenerative diseases. Under the terms of the agreement, Kiora received an upfront payment of $16 million, recognized as collaboration revenue, and is eligible to receive up to an additional $285 million in development, regulatory, and commercial milestones&#59; tiered royalties of up to low 20 percent on net sales&#59; and full reimbursement of future KIO-301 research and development expenses.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Reported quantitative functional MRI results at the Association of Research in Vision and Ophthalmology (ARVO) annual conference from ABACUS-1, showing a statistically significant increase in neural activity over baseline specifically within the brain&#8217;s visual processing center. This increase in observed brain activity was time-dependent and concordant with previously reported improvements in visual field, visual acuity, and functional vision.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">KIO-104 </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Publication of results from a Phase 1 double-masked study of KIO-101 in the medical journal </font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Pharmaceutics, </font><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">documenting a 12-day treatment of KIO-101 topically at multiple doses was well tolerated in healthy volunteers and patients with inflammation of the eye. There was a significant decrease in conjunctival hyperemia in the treatment group compared to placebo.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Initiated Investigational New Drug enabling preclinical work in support of planned phase 2 retinal inflammation clinical trial.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Kiora anticipates achieving the following clinical and regulatory milestones&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.030%"><tr><td style="width:1.0%"></td><td style="width:71.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">KIO-301</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Type D meeting with the FDA for functional vision endpoint</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1H 2024</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Initiate ABACUS-2 clinical trial</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2H 2024</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">Begin design of additional inherited retinal disease studies</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1H 2025</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">KIO-104</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Complete non-clinical package</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2H 2024</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">&#8226;</font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Initiate Phase 2 clinical trial</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1H 2025</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Financial Results Highlights </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Kiora ended the first quarter of 2024 with $31.3 million in cash and cash equivalents plus $1.8 million in research and development incentive tax credits and $0.2 million in collaboration receivables from TOI. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Revenue was $16.0 million for the first quarter of 2024, compared to no revenue in the first quarter of 2023. The revenue comes from collaboration revenue as part of an upfront payment from TOI connected to the strategic development and commercialization partnership. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development expenses were $1.5 million, net of $0.2 million in offsetting credits related to expenses for KIO-301 which will be reimbursed by TOI, for the first quarter of 2024, compared to $0.4 million, net of $0.3 million in offsetting tax credits, for the first quarter of 2023. The increase was primarily due to a one-time licensing payment made to the University of California related to a sublicense fee of $0.7 million, and a decrease of $0.3 million in R&#38;D tax credits due to reduced credit-eligible expenses given the KIO-301 expenses are now being reimbursed by TOI.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">General and administrative expenses were $1.3 million for the first quarter of 2024, compared to $1.3 million for the first quarter of 2023. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net income was $13.5 million for the first quarter of 2024 compared to a net loss of $1.9 million for the first quarter of 2023. The change in income is attributable to the recognition of $16 million in collaboration revenue. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">About Kiora Pharmaceuticals</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and&#47;or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase. In addition to news releases and SEC filings, we expect to post information on our website, </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">www.kiorapharma.com</font><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and&#47;or subscribe to email alerts.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Forward-Looking Statements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Some of the statements in this press release are &#34;forward-looking&#34; and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These &#34;forward-looking&#34; statements include statements relating to, among other things, Kiora's ability to execute on development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's development-stage products, including KIO-104, KIO-301, KIO-201 and KIO-101, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all, the sufficiency of existing cash on hand to fund operations for specific periods, the projected cash runway, the ability to timely complete planned initiatives for 2024, including phase 2 clinical development of KIO-301 and KIO-104, the potential for KIO-301 to be the first treatment options for patients with inherited degenerative diseases like RP, Kiora's plans to further fund development of KIO-104, the potential for KIO-104 to reduce inflammation, the timing of topline results from a Phase 2b trial of KIO-104, the potential for KIO-104 to apply to other retinal inflammatory diseases, and expected trends for research and development and general and administrative spending in 2024. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the ability to satisfy the closing conditions related to the offering ,the ability to conduct clinical trials on a timely basis, market and other conditions and certain risk factors described under the heading &#34;Risk Factors&#34; contained in Kiora's Annual Report on Form 10-K filed with the SEC on March 25, 2024 or described in Kiora's other public filings including on Form 10-Q filed with the SEC on May 10, 2024. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contact Information&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors&#64;kiorapharma.com</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Tables Follow</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i5b6fb9a4f2d94338a3cf614aec689634_51"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2024 <br>(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash Equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,276,330&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,454,684&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid Expenses and Other Current Assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,671&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,382&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration Receivables</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,905&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Receivables</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,808,787&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,049,965&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current Assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,481,693&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,738,031&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current Assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and Equipment, Net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,918&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,065&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Cash</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,084&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,267&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible Assets and In-Process R&#38;D, Net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,807,600&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,813,850&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Assets with Right-of-Use</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,298&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,890&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,414&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,767&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,440,007&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,711,870&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts Payable</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,062&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,260&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued Expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222,078&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380,666&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,851&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,069&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current Liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592,991&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,633,995&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current Liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Consideration</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,116,765&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,128,959&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Tax Liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779,440&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779,440&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,448&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,822&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-Current Liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,942,653&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,968,221&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,535,644&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,602,216&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and Contingencies (Note 8)</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; Equity&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred Stock, $0.01 Par Value&#58; 10,000,000 shares authorized&#59; 3,750 designated Series A, 0 shares issued and outstanding&#59; 10,000 designated Series B, 0 shares issued and outstanding&#59; 10,000 shares designated Series C, 0 shares issued and outstanding&#59; 20,000 shares designated Series D, 7 shares issued and outstanding&#59; 1,280 shares designated Series E, 0 shares issued and outstanding&#59; 3,908 shares designated Series F, 420 issued and outstanding at March&#160;31, 2024 and December&#160;31, 2023, respectively</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:7.2pt;text-indent:-7.21pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common Stock, $0.01 Par Value&#58; 50,000,000 shares authorized&#59; 26,256,197 and 7,705,640 shares issued and outstanding at March&#160;31, 2024 and December&#160;31, 2023, respectively</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,584&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,078&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional Paid-In Capital</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,429,797&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,192,228&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Deficit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133,523,648)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146,976,855)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Loss</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(264,374)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182,801)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Stockholders&#8217; Equity</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,904,363&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,109,654&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities and Stockholders&#8217; Equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,440,007&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,711,870&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i5b6fb9a4f2d94338a3cf614aec689634_46"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KIORA PHARMACEUTICALS, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPREHENSIVE INCOME (LOSS)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration Revenue</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,000,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenue</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,000,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and Administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,296,441&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,269,458&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and Development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,493,659&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438,283&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.96pt;text-align:left;text-indent:-5.77pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in Fair Value of Contingent Consideration</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,194)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,926&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,777,906&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916,667&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Income (Loss)</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,222,094&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,916,667)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Income, Net&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Income, Net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,047&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,465&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Income, Net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,066&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,666&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other Income, Net</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,113&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,131&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income (Loss)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,453,207&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,868,536)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.21pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income (Loss) per Common Share - Basic</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.52&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.00)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.21pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Shares Outstanding - Basic</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,936,163</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,863,466</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.21pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income (Loss) per Common Share - Diluted</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.38&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.00)</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.2pt;text-align:left;text-indent:-7.21pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Shares Outstanding - Diluted</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,025,494</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,863,466</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Comprehensive Income (Loss)&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income (Loss)</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,453,207&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,868,536)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.96pt;text-align:left;text-indent:-5.77pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,573)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,671)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive Income (Loss)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,371,634&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,901,207)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>kprx-20240510.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3652cabc-38b6-450f-a909-c9466ceb4b5c,g:bc80bc13-a467-4786-8c57-b0dd8a605c36-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:kprx="http://www.eyegatepharma.com/20240510" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.eyegatepharma.com/20240510">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kprx-20240510_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kprx-20240510_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.eyegatepharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>kprx-20240510_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3652cabc-38b6-450f-a909-c9466ceb4b5c,g:bc80bc13-a467-4786-8c57-b0dd8a605c36-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_b332c00a-8753-46c9-8ade-9687b95b23ee_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_13e24182-9dec-4062-aa21-b447b5bd94dd_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_651487ea-e841-49cf-b593-de34e3d50a32_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7248ec73-6318-47df-95f1-c1f9832b5fa7_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c76f356e-f3a3-4bf6-a9c4-8a3e5a3e8de6_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4eefe356-d671-4086-95cc-bfb06dcb7bbf_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_fb664627-8548-4c15-8f51-5d07980e90f0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_9e05904f-9159-4844-8a57-6938b4d585fa_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_4ddc948c-5822-4079-a633-cce677acb2d3_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ec710d42-ce9c-4cd6-8e36-37e938feda22_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_4a39056e-546d-4228-a26b-810b5a862ee1_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_950877cb-9687-48a0-877f-67a7e7716e42_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f00c5d64-d2a6-43a0-8120-18e964c1112f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2491fdb3-eab2-4baa-a60d-31538ebdf096_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_3b4fdaa5-41b1-4c50-8513-6e3c15cc6059_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_590aa794-469a-4a93-8b35-ef578b563706_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_644fa0a9-4f15-44de-b37a-59b8ff852a29_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_bb61dfde-8c46-453a-b1ed-fbb4ed837da0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c21cff19-de33-4c89-a613-966b1cac6d82_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_11e0f2f0-892b-4a94-8293-d5b8e5b19ff5_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ae295a3f-fb76-4196-b8cf-8504aa7313fe_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_92fa8f63-1869-4236-aba5-ad731b3deba3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e7e9f2fb-718c-4bc4-b7ef-5cd85408678d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>kprx-20240510_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:3652cabc-38b6-450f-a909-c9466ceb4b5c,g:bc80bc13-a467-4786-8c57-b0dd8a605c36-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/Cover" xlink:type="simple" xlink:href="kprx-20240510.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_861133f8-f1f4-4fb7-bd0a-62d535a5bea4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6745ed99-f5c1-40db-8216-8118d2fb6462" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861133f8-f1f4-4fb7-bd0a-62d535a5bea4" xlink:to="loc_dei_DocumentType_6745ed99-f5c1-40db-8216-8118d2fb6462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_36740302-581d-4d3d-b2fa-21cd7f47a6da" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861133f8-f1f4-4fb7-bd0a-62d535a5bea4" xlink:to="loc_dei_DocumentPeriodEndDate_36740302-581d-4d3d-b2fa-21cd7f47a6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_10fdee7f-bb0b-4991-ab1f-4fe2e4d1acd9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861133f8-f1f4-4fb7-bd0a-62d535a5bea4" xlink:to="loc_dei_EntityRegistrantName_10fdee7f-bb0b-4991-ab1f-4fe2e4d1acd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4ef5ee91-8b99-4170-b838-e4aad334a0a4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861133f8-f1f4-4fb7-bd0a-62d535a5bea4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4ef5ee91-8b99-4170-b838-e4aad334a0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_60225361-9102-4062-82f1-76e07ec126cf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861133f8-f1f4-4fb7-bd0a-62d535a5bea4" xlink:to="loc_dei_EntityTaxIdentificationNumber_60225361-9102-4062-82f1-76e07ec126cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a13b19d9-502d-458d-abcb-7dc375991456" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861133f8-f1f4-4fb7-bd0a-62d535a5bea4" xlink:to="loc_dei_EntityFileNumber_a13b19d9-502d-458d-abcb-7dc375991456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_37bd04e3-6426-4242-b994-4daf943687ba" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861133f8-f1f4-4fb7-bd0a-62d535a5bea4" xlink:to="loc_dei_EntityAddressAddressLine1_37bd04e3-6426-4242-b994-4daf943687ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_e7ebe6cb-694c-4877-97cb-6cbc62cac0b2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861133f8-f1f4-4fb7-bd0a-62d535a5bea4" xlink:to="loc_dei_EntityAddressAddressLine2_e7ebe6cb-694c-4877-97cb-6cbc62cac0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_af524183-9d31-4eac-91b8-b3bba65076d6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861133f8-f1f4-4fb7-bd0a-62d535a5bea4" xlink:to="loc_dei_EntityAddressCityOrTown_af524183-9d31-4eac-91b8-b3bba65076d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_dc35c2eb-0e80-475f-8ed8-aea4a30a6e5e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861133f8-f1f4-4fb7-bd0a-62d535a5bea4" xlink:to="loc_dei_EntityAddressStateOrProvince_dc35c2eb-0e80-475f-8ed8-aea4a30a6e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b05bb3c3-31e8-4bc8-ab0c-bd1b9b63184b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861133f8-f1f4-4fb7-bd0a-62d535a5bea4" xlink:to="loc_dei_EntityAddressPostalZipCode_b05bb3c3-31e8-4bc8-ab0c-bd1b9b63184b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_61c3d92c-e6a1-4952-babf-d0fd15d88a8c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861133f8-f1f4-4fb7-bd0a-62d535a5bea4" xlink:to="loc_dei_CityAreaCode_61c3d92c-e6a1-4952-babf-d0fd15d88a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6da78ef5-1a42-4b4e-a4d2-7f76b48f79f4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861133f8-f1f4-4fb7-bd0a-62d535a5bea4" xlink:to="loc_dei_LocalPhoneNumber_6da78ef5-1a42-4b4e-a4d2-7f76b48f79f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_8008af5a-c405-4cd4-9f94-a38c9727e7bc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861133f8-f1f4-4fb7-bd0a-62d535a5bea4" xlink:to="loc_dei_WrittenCommunications_8008af5a-c405-4cd4-9f94-a38c9727e7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_a927a3f9-b785-448c-a08a-0f3237e6782a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861133f8-f1f4-4fb7-bd0a-62d535a5bea4" xlink:to="loc_dei_SolicitingMaterial_a927a3f9-b785-448c-a08a-0f3237e6782a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_41716ca5-e95c-4ab9-9eb4-d271d1572f60" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861133f8-f1f4-4fb7-bd0a-62d535a5bea4" xlink:to="loc_dei_PreCommencementTenderOffer_41716ca5-e95c-4ab9-9eb4-d271d1572f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_46dbdff5-feb0-491d-8639-0aa3bbc166cd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861133f8-f1f4-4fb7-bd0a-62d535a5bea4" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_46dbdff5-feb0-491d-8639-0aa3bbc166cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_52df1529-3049-406e-8b1e-ab796f1b94b3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861133f8-f1f4-4fb7-bd0a-62d535a5bea4" xlink:to="loc_dei_Security12bTitle_52df1529-3049-406e-8b1e-ab796f1b94b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3d0f0954-3925-4669-ad0c-7da72a18b522" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861133f8-f1f4-4fb7-bd0a-62d535a5bea4" xlink:to="loc_dei_TradingSymbol_3d0f0954-3925-4669-ad0c-7da72a18b522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_be8fb2a5-365d-44b8-8317-6fcd82075ade" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861133f8-f1f4-4fb7-bd0a-62d535a5bea4" xlink:to="loc_dei_SecurityExchangeName_be8fb2a5-365d-44b8-8317-6fcd82075ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2b7d1a83-0e86-45d4-8aa5-c2b7711daa43" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861133f8-f1f4-4fb7-bd0a-62d535a5bea4" xlink:to="loc_dei_EntityEmergingGrowthCompany_2b7d1a83-0e86-45d4-8aa5-c2b7711daa43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_434aa4b0-a51b-4e4c-846f-25e8b964fd0a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861133f8-f1f4-4fb7-bd0a-62d535a5bea4" xlink:to="loc_dei_EntityCentralIndexKey_434aa4b0-a51b-4e4c-846f-25e8b964fd0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ee35604d-2c78-4a44-99a6-c76d0ff82b31" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_861133f8-f1f4-4fb7-bd0a-62d535a5bea4" xlink:to="loc_dei_AmendmentFlag_ee35604d-2c78-4a44-99a6-c76d0ff82b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>businesshighlightsa.jpg
<TEXT>
begin 644 businesshighlightsa.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '+ ^<# 2(  A$! Q$!_\0
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M%%?5'@A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9O#VH^&K:WMGL;.SU:)H[EHDB?$C@]V)/K777WQ6T/QQX,\%_P#"JOV@=/\
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M!&*^RZY23_D9M8_W;?\ ]!>MZ-:5&7/#<SJ4XU5RRV/SW_X=2ZE_T4"T_P#
M%O\ XJC_ (=2ZE_T4"T_\ 6_^*K]$**[O[2Q'=?<CG^I4>S^\_.__AU+J7_1
M0+3_ , 6_P#BJ/\ AU+J7_10+3_P!;_XJOT0HH_M+$=U]R#ZE1[/[S\[_P#A
MU+J7_10+3_P!;_XJC_AU+J7_ $4"T_\  %O_ (JOT0HH_M+$=U]R#ZE1[/[S
M\[_^'4NI?]% M/\ P!;_ .*H_P"'4NI?]% M/_ %O_BJ_1"BC^TL1W7W(/J5
M'L_O/SO_ .'4NI?]% M/_ %O_BJ/^'4NI?\ 10+3_P  6_\ BJ_1"BC^TL1W
M7W(/J5'L_O/SO_X=2ZE_T4"T_P# %O\ XJC_ (=2ZE_T4"T_\ 6_^*K]$**/
M[2Q'=?<@^I4>S^\_._\ X=2ZE_T4"T_\ 6_^*H_X=2ZE_P!% M/_  !;_P"*
MK]$**/[2Q'=?<@^I4>S^\_.__AU+J7_10+3_ , 6_P#BJ/\ AU+J7_10+3_P
M!;_XJOT0HH_M+$=U]R#ZE1[/[S\[_P#AU+J7_10+3_P!;_XJC_AU+J7_ $4"
MT_\  %O_ (JOT0HH_M+$=U]R#ZE1[/[S\[_^'4NI?]% M/\ P!;_ .*H_P"'
M4NI?]% M/_ %O_BJ_1"BC^TL1W7W(/J5'L_O/SO_ .'4NI?]% M/_ %O_BJ/
M^'4NI?\ 10+3_P  6_\ BJ_1"BC^TL1W7W(/J5'L_O/SO_X=2ZE_T4"T_P#
M%O\ XJC_ (=2ZE_T4"T_\ 6_^*K]$**/[2Q'=?<@^I4>S^\_._\ X=2ZE_T4
M"T_\ 6_^*H_X=2ZE_P!% M/_  !;_P"*K]$**/[2Q'=?<@^I4>S^\_.__AU+
MJ7_10+3_ , 6_P#BJ/\ AU+J7_10+3_P!;_XJOT0HH_M+$=U]R#ZE1[/[S\[
M_P#AU+J7_10+3_P!;_XJC_AU+J7_ $4"T_\  %O_ (JOT0HH_M+$=U]R#ZE1
M[/[S\[_^'4NI?]% M/\ P!;_ .*H_P"'4NI?]% M/_ %O_BJ_1"BC^TL1W7W
M(/J5'L_O/SO_ .'4NI?]% M/_ %O_BJ/^'4NI?\ 10+3_P  6_\ BJ_1"BC^
MTL1W7W(/J5'L_O/SO_X=2ZE_T4"T_P# %O\ XJD;_@E/J*J3_P + M>!G_CQ
M;_XJOT1ILG^K?_=/\J7]I8CNON0?4J/9_>?G=#_P2JU&:%)!X_M0& ./L+?_
M !5/_P"'4NI?]% M/_ %O_BJ_0FQ_P"/. _[ _E4]/\ M+$=U]R#ZE1[?B?G
M?_PZEU+_ **!:?\ @"W_ ,51_P .I=2_Z*!:?^ +?_%5^B.#G&.:-I'48H_M
M+$=U]R#ZE1[/[S\[O^'4NI?]% M/_ %O_BJ/^'4NI?\ 10+3_P  6_\ BJ_1
M)8V89"L1Z@4VE_:6([K[D'U*CV?WGYW_ /#J74O^B@6G_@"W_P 51_PZEU+_
M **!:?\ @"W_ ,57Z(JI8X R?:@J5.",'TH_M+$=U]R#ZE1[/[S\[O\ AU+J
M7_10+3_P!;_XJC_AU+J7_10+3_P!;_XJOT1967[RD?44F#C..*/[2Q'=?<@^
MI4>S^\_._P#X=2ZE_P!% M/_  !;_P"*H_X=2ZE_T4"T_P# %O\ XJOT0HI_
MVEB.Z^Y!]2H]G]Y^=_\ PZEU+_HH%I_X M_\51_PZEU+_HH%I_X M_\ %5^B
M%%']I8CNON0?4J/9_>?G?_PZEU+_ **!:?\ @"W_ ,51_P .I=2_Z*!:?^ +
M?_%5^B&#C..* "> ,FC^TL1W7W(/J5'L_O/SO_X=2ZE_T4"T_P# %O\ XJC_
M (=2ZE_T4"T_\ 6_^*K]$*,&E_:6([K[D'U*CV?WGYW_ /#J74O^B@6G_@"W
M_P 51_PZEU+_ **!:?\ @"W_ ,57Z(44_P"TL1W7W(/J5'L_O/SO_P"'4NI?
M]% M/_ %O_BJ/^'4NI?]% M/_ %O_BJ_1"EP<9QQ1_:6([K[D'U*CV?WGYW?
M\.I=2_Z*!:?^ +?_ !5'_#J74O\ HH%I_P" +?\ Q5?HA11_:6([K[D'U*CV
M?WGYW_\ #J74O^B@6G_@"W_Q5'_#J74O^B@6G_@"W_Q5?HA1@TO[2Q'=?<@^
MI4>S^\_._P#X=2ZE_P!% M/_  !;_P"*IK?\$H]0;KX_LS];!O\ XJOT2HI_
MVEB.Z^Y!]2H]G]Y^=W_#J74?^B@6G_@"W_Q5+_PZEU+_ **!:?\ @"W_ ,57
MZ(44?VEB.Z^Y!]2H]G]Y^=__  ZEU+_HH%I_X M_\51_PZEU+_HH%I_X M_\
M57Z(44?VEB.Z^Y!]2H]G]Y^=K?\ !*/4&Y/CZS)][!O_ (JG?\.I=1_Z*!:?
M^ +?_%5^B(!/09I*/[2Q'=?<@^I4>S^\_.__ (=2ZE_T4"T_\ 6_^*H_X=2Z
ME_T4"T_\ 6_^*K]$**/[2Q'=?<@^I4>S^\_._P#X=2ZE_P!% M/_  !;_P"*
MH_X=2ZE_T4"T_P# %O\ XJOT0HH_M+$=U]R#ZE1[/[S\[_\ AU+J7_10+3_P
M!;_XJC_AU+J7_10+3_P!;_XJOT0HH_M+$=U]R#ZE1[/[S\[_ /AU+J7_ $4"
MT_\  %O_ (JC_AU+J7_10+3_ , 6_P#BJ_1"BC^TL1W7W(/J5'L_O/SO_P"'
M4NI?]% M/_ %O_BJ/^'4NI?]% M/_ %O_BJ_1"BC^TL1W7W(/J5'L_O/SO\
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M78'S&,N60KZ%2>:X^;X#IX9^$_BWP]H5S<:SJVKA!'=:G(/,$:.GDV^[LD:
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MG^DR[2-PP1U!]*;X=^&/B*TU3PMJ^H);"_;Q)>:]JT,$N4M5FMS$D:'^,@!
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M_$?O;H]*HH/4T5S'0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!2U+_ (^-*_Z_HOYFNPKC]2_X^-*_Z_HOYFNPI]".
MH4444@"N4D_Y&;6/]VW_ /07KJZY23_D9M8_W;?_ -!>FMF'4L5S-M\1-&NO
MB3>^!8WF.OVFFQZK*AC/E^0[E%(;N<CI735\Q>+KR?3_ -J#XIW=M*T%S!\,
M1+%+&<,CK*Y# ]B#6M."G=>1,Y.-CZ>V,!DJ<?2C8W]T_E7QOX?;Q-X.\'_
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M=\)CPCXI\,C3G_L7Q///<ZK;^>V9Y)L>80W5<X'3I7:457/+N3RQ['G?C+X
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M_:(M9]0FDLA=?\]A 6V[P>1Z&O2**?M9_P S%[.'85F+$D\DTE%%9&@4444
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M:T?#/B;3O%UG+>:9*UQ:1W,MH92A57>-BC[<]5W C/?%)Q:W0U)/8U**\?\
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M@D<2&1GDQM"85<$\=:L6?QN\+WUY:QH]^EA=W/V.VUB6R=;">;)4(LQ&.2"
MQPI/0FE[.78KGCW.]HKC;+XLZ#JGC*Z\,6"7]_JEE<FTOC;VC-#9R 9'FR=%
MR.G7-=E4N+CN--/8****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *6I?\?&E?]?T7
M\S785Q^I?\?&E?\ 7]%_,UV%/H1U"BBBD 5RDG_(S:Q_NV__ *"]=77*2?\
M(S:Q_NV__H+TULPZEBBBBD6%%%% !1110 4444 %%%% !1110 4444 %%%%
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M7'GQ&- KCU'!KN:**SD^9W+2Y58****DH**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *6
MI?\ 'QI7_7]%_,UV%<?J7_'QI7_7]%_,UV%/H1U"BBBD 5R;K*WB;6!'!)+\
MEORF/[K>]=96+IO_ ",VM?[MO_Z"U4MF!6\JY_Y])OR'^-'E7/\ SZ3?D/\
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M;M:780N(F5F;>C*KX;@Y7D<U'9_$WQ/>_&JP\/3:$FE>%KFVO?)N+PD7=U+
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M6/IRBOE'Q5^U!XY\"^"?B#::GI.DW?CKP=JFFVA:VWK9ZA!=NHCD4$[HV(+
M@DX(KZ ^&D/C:/0YG\=W.D3ZK+,TD<>C1.D4$1 Q&2Y)9AR-W&:B5*4%S/\
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M?C-K?CU[_P Y=4T:#1VTUH1M41R.^_=GG._&,=J[^BA2<;V!I/<\;\2?LO\
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M34)M4TZP<F%64*+:7:#A78M(H(P6 ]J]Q;PSI#6M_;-IEHUO?DM=Q&!2LY(
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M4G]Q?R%'EI_=7\J L=!]IB_YZI_WT*/M<'_/:/\ [Z%<_P"6AZJOY4GD1_\
M/-?^^10%C?-];#@W$0/^^*!?6QZ7$9_X&*Y_[/%_SR3_ +Y%*((UZ1H/^ B@
M+&_]LM_^>\?_ 'T*?]HB_P">J?\ ?0KGO*3^XOY"CRU_NK^5 6.@-U"O66,?
M\"%(;R =9HQ_P,5SYA1NJ*?PH\B/_GFO_?(H"QO?;[;_ )^(O^^Q2_;K<])X
M_P#OL5S_ -GB_P">2?\ ?(I?)C'2-1_P$4!8Z 7D#' FC)_WA3OM$7_/5/\
MOH5SWEI_<7\J/+7^Z/RH"QT'VJ'_ )[1_P#?0IK7MNO6>,?\#%8'DQ_\\U_[
MY%'V>+_GFG_?(H"QO?;[;_GXB_[[%.^V6_\ SWC_ .^A7/?9XO\ GDG_ 'R*
M=Y2?W%_(4!8Z!;J%N1+&?^!"C[3#_P ]4_[Z%<_Y:?W5_*CRT/&Q?RH"QO\
MVN#_ )[1_P#?0I#?6PX-Q$#_ +XK \B/_GFO_?(I/L\7_/)/^^10%CH/MUL>
MEQ$?^!BE^V6__/>/_OH5SX@C'2-!_P !%+Y2?W%_(4!8Z'[1%_SU3_OH4GVJ
M$=98Q_P(5S_EK_='Y4AA1NJ*?PH"QT'VR #)FCQ_OBF_;[;_ )^(O^^Q6#Y$
M?_/-?^^12?9XO^>2?]\B@+'0?;K<])XS_P #%*+R!N!-&3_O"N?\F,=(U'_
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MP:WB[X=ZCX8EOG$UW8"U^WNN6\P*-LI'?YE!(^M=+12YWIY%<JU\SRI/#/Q
M\2^)/!%[X@@T'3K/P[>-<W"6-P\SWA-O)%N7(&P?/G;UY]JHZ#\-/$/@MI]'
MTWP[X3UO2&O9;FVU;4E"W,$<DID9)$"DR,I9@K \C&>E>Q,P12S$*JC)9C@
M>IH1UD171E=&&593D$'H0:KVCVMH3[-'E?Q ^#MYXN^(VC:M:7T-KX?G6%/$
M=BP(:^6W;S+7;]'X;/\ "HJ3Q%\/]8T_QYK7B+1-#\/^)+?7$A-U9ZUB-[>>
M--@DC<J<HRA<KV(XZUZC12]I+8?LT>:ZM\+[SQ-JFB2ZBNGV=G'H-_I5];Z:
MI1$DN/+P85(^Z-AZ^U94O@3QWXGT'0_"7B$Z/#H6G3VSW>K6<S-<7\=N08U6
M(C$9;:NXDG'.*]?HH]I)!R(\+\,KXZN-1^*5AX=M-'-K>^([N)-0OYG1[0M&
MJLYC _>8SE0".>M=IX(^&,G@CQ7:7%O.DVD6?ANVT2+<?WK212.Q<CT(85WZ
MJJYVJJY.3M&,GU/O2TY5&]A1@D>7:?\ "[5K/X>^#-":>U-[HNN0:G.X8[&C
M2Y>4A3W;:P_&L^V^&>O>$=4UNWT7P[X5\0:5J5_+J$%WK.$GLVE(,B.-I,B@
MY*X(/.*]AHI>TD'LT<GX5\)WFA^.?%FM7#VYM=6CL4@C@R"AAAV/D=AGI[5Q
M:?##Q-H?@SP+#IPTZ^UKPUJDU^]M<3F.&X219DVB3'! E!Z=B*]>\Z/S?*\Q
M?-V[O+W#=M]<>GO3J7M&G_7H/D1DZOIEUX@\(W^FW)AMKV^L)+:1HB6CCD>,
MJ<9Y*@G\J\^T?P+XMO-!^'UEK,&E64GA74K:5OLERTHN((K=HB_(X9B00O89
MKU>BE&;BK(;BGJ>7?$3X6ZMXMU'QE<6<]K&FL^'H=)MQ,Q!69)G<EO1<,*V_
M'G@_5M4D\+ZQH,MJ-=\/3&6*"])$%U&\1BEB9ARI(.0W8@5VU%/VCT\A<B/)
MK_X7Z_X\'BS4/$TMCI.I:KI']C6%I82&>.TB#^9OD<@;V:0+D#H!1'X9\?:W
MXD\$:MK]KHMC:>%WEFFM]/N'GFO&-N8PR$@!02!A>O->LT57M9"]FCY&^'NH
M1^$[/2?$,3>&_$FL7.J-+'HC/<#4X7GF(<+%GRTE17.3M PIYKWG2OA]J.G^
M&?B#ITDUN9_$%]>W-JRL=J+-$J*']""IS7<I8VL=TUTEI;I=-]Z=85$A^K8S
M4]5.KS.Z0HT^569E>#=+E\.^$] TRY97N+"PM[65HSE2T<2HQ'MD&L'X0^!Y
MOA]X'L-)O4LVU*%YVDN+5!\P>5G'S8R>&%=D&5F(# E>H!Y'UI))4AC:25UC
MC7EG=@ /J36/,]5W-.5:/L<OX=\*W>D^,O&FK321-;:TUNUNJ$[E\N 1MN].
M:\SLO@WXGTG3O"%G/::7XFL=+TZ6TETRZOG@MX;EIS(+@ ?ZWY#MVGIVKW:B
MK522_KY$N"9XMH_PKU[P[\,=,\*W/AOPOXMMXYKJ6XM;J5H(XFDD9XVA)!V@
M!L'HW'!IUO\ !W7?#^F^#;RV_LKQ1K6BZ?)IM[9ZR28;F%WWJ(Y'#%6C/ +=
M0>:]F9E7&Y@N3@9.,GTI(YHYMWER+)M8JVU@<,.H/H?:G[60O9Q,/P38ZC8Z
M2W]J:5I&CW,DI<6>C#,2+QC<V!N;U(&*YC4K7XEZ1?ZW:Z-_8VOZ7J$C26=S
MJUPT,FGAU :)T4?O8U.2N.>2#7HM%0I6=[%<NECG_A[X13P#X'T7PZEP;P:=
M;B)K@KM\QB2S$+V&2<#L,5T%%%2VV[LI*RL@HHHI#"BBB@ HHHH **** *6I
M?\?&E?\ 7]%_,UV%<?J7_'QI7_7]%_,UV%/H1U"BBBD 5RDG_(S:Q_NV_P#Z
M"]=77*2?\C-K'^[;_P#H+TULPZEBBBBD6%%%% !1110 4444 %%%% !1110
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M\!^+O#>G^)M8LO$6DZ_,UB+JWLOLLEG>!"Z@ ,0\3!6&3@@@>M0V_CKQ=/\
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M"],'K7KWPM\&^._ /D6]V_A>\BGN/M.JZDCW+7U[*?O2$LH7/8+T4<"J]O\
M#7QGX9T#6_"OAW5-#_X1W4IKJ2&ZU"*4W=FEP295VJ-DI!9MI)';-:*:3U=_
M^'_K0AQ;6B*_Q \+ZGXHU+P#<3^&8OB%HMCITTETJ74,<4MTZ1*DN)& 8$"0
MCZUV?PJU+0-0\*LGA[1SX>M[2ZEM;K27B$;VMRI'F(P!(SR#D$@@@U6/A[Q9
MX1T?0M(\'3Z+/I>G6,=D8]<$JR$H,"0/&#GCJI%:/P\\&S^#='O$OK]=3U?4
MKV74M0NTC\M'GDP"$7LBJJJ,\X7/>L)23A:_H:Q34KGD_B'5+[P-\?/%GC1+
MB>70;6#3-/UNR!)1+>1&VW2KV,;XW?[)/I47QPUBY\;>)-/M]-O7C\/>$];T
MQ[R:W?"WE]+.@2'(ZI'&VX^[@=J]<L_!07Q7XPU&]:&[T_7[>VMFM&4G"QQL
MCAL\$-N[5B3_  9TS2OAUIWA#PR%TNQL]2MK\&X9I6?RYUE?<W5F;&,GVK15
M(IIO=6(<)6:.&\7:E?>"?C[XF\:Q332Z+866GV>MV8)*"TD,G^DJO]Z)\$^J
MEJJ?'W6KKQMJ=K::5>LGA_PMJNFSWT]N_P MY>2S+Y4&X=51#O;W917L5KX.
MV^,O%6K73PW-CK=I;VIM&4DA8PX8-G@@A_TKG;OX*Z5I?PSM_!GA=5TJRAU"
M"^#7#-*6*3"1MS'DD@!03T  [41J133>ZL#A*S1T_P 5)K2W^'_BV6^LDU*R
MCT^X>:RD8JLZ!22A(Y ..HKCX?'7B&X\0:?X3\*:!IH">'[/5!=:C=ND%NDA
M9%BVJI9C\G!^N:[KQUH<GBWPCX@T>&5;>74K.:V260$JA=2 3CL,UB^&O MQ
MH7C4:W)=Q2P_V!9Z/Y*J0V^%W8OG^Z=XP.O%91<5'7<T:?-H6_AOXPE\>>&8
M]0N+(:=?QW,UE=VJR>8L<\4AC<*V!E25R#CH17F_Q \>>*/%G@'Q_=>'M%TV
M7PU807E@9[R[>.YNVC4K*\2A2JJIR!N/S;3TKTCX=^$Y_!.EW]K/<1W3W.JW
M>H*T8("K-*7"G/< X-<-J'PJ\86V@^*_"VAZWI%KX;UN6YFAN+N"1[NR\_F2
M-5'R.NXDAB<C<>*J/(IMDRYN5$,GQ<.@Q^&?"VES:-;ZC'H%I?W-YKUVT$$:
M,@5$4*I9W;!/H!6OX*^,Y\5:OX>M9]-CL[;5UN[5;F.?S$%_;/AX5. &1D!=
M&[A3Q3I_AKK6A:QIFM^')])GOTT>WTC4+/5XW,%PL(_=RHR@LK DC!&""*L^
M-_A_KWC;X<QZ>VK:?I7C"UG6^L-4LK=EM[2X5CM(3J5V%D/<@FJ?LW87OF)K
M7Q\%BLOV:RLU2\UN71=(NKZZ,-O,88RUQ/*V#M16#* N2Q6N<\=?$M_&7PS\
M:Z1='3Y-1TJ33Y&N]'N&FM)XI+F/:RL0"K @@J>E=QJ'PB:R\+^#;3P[=V]K
MJOA5O,M)+^(R07):,I,LP'/[S<QW#D$YIWB#P/XG\:^!=9T?6+C0M/N;R6!K
M==+AD\J)8Y5=M[, S$[?3 IITU9K^M?\A-3=TRQJ7C?Q/K?BK7=)\'Z1IEW%
MH31PWEUJUT\0FN&0/Y$016Z*1EFX!-8UK\9M4\43>%;3PSH,+W>NV5W<2?VG
M<F-+"2WD6.1)-H);#%A\O7 [5K7G@_Q7X>\5^(-6\(7VCBVUYTN+JUUA)?\
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M+X6F7XH7?BK[1']FFT>/3!;8.\,LTDF_/3&' _"N6\%_"6\\+MX%,NH6\_\
MPCJZ@LWEHP\[[0S%=N>FW/.:5X6V_JS_ %L.T^Y@'XT>,(=#UO6[CPOIL6F^
M&;[^S]907KF:9U90\EL-N"@61& ?!.2.U:/BCXV36WBO6]'T1] C710@N9-<
MOVMVN963?Y4*JIQA2 7;C)Q6CJ'PIO+SP3X_T-=0MUF\2ZC+>PS%&VP*_E85
MAU)'EGIZBBY\!^)?#_B?6-4\+S:%<VVL^5+=6>MPO^XN$C"&6-D!R& !*GN.
M#5?NWT_K3_@B]\S3\9-<\4:OX7TWP?H%K<2:[HAUG[3JUPT45FJR!&1PJDL<
MG Q_*M6U\=>+/%&KZM%X:TC29M.T:Y^P75QJ-W)&UU<JJF580J'"KN W-U/:
MM>R\&W\?Q!TSQ-=WMM*]OH;:7-'!$8P\K3+(9%'15XQCK6/;^"O%WA/6]>;P
MK?Z*='UJ].H/%JT<IELIW"B4Q[!AU;:&PQ&"34^YT'[W4=I>I&#Q3\2&T'P]
M;/KMO-9^<\EV8EO':'(:1B"$"#C@<BN+\>^/M1USX?\ Q'\.ZS'I8U33=.@N
MEN=%NFFMY89) !RP!5U92"#UZUTGC#X0ZKKR^+9+75+59-9O;"[%O,)$AF2W
M7#P3%>=DG^S67)\#=5OK?Q@TDF@:,^O:5;Z=#9:/:M'!:^7*7W,< OD'K@&K
MBZ>C;[?H3+GV2[_J>G^)-<;PSX)U'6%B%PVGZ>UT(2<!RD>[;GMG%><1_%+Q
MV]_X8LF\+Z1%<>*K<SZ8?M[LEGLC$CBY(3GY#D;,\C'O7H_BO09/$7@O5M$B
MF2&:]L'LUF<$JK,FW<0.<5B_\(%<?VQ\/[S[7%L\-6\L$R[3F<O;^4"OI@\\
M]JR@XI:K^K?YFDE*^AR4_CB/Q/;^&D\1^';5]8L/&::-+''<,T-O<JC,MS$V
M 6&W&%8=SGI63I'Q(B^'6B^)G*6\VHZIXVOK&S2\G\F .6+,\CX.U%523@$G
M@#K76-\)[QM4^U?VA;[?^$P'B;;L;/E"(IY7^]DYSTJM=?!V_P#L-S/::G:1
M:W#XEN/$.G330EX%\W*M#*O4@HQ!(Z'!'2M>:GMT,[3W,JX_:"FTG1?$;7=M
MI6IZCI*6TJ76DW;R6$D<\GE[Y'*[HQ&>7X/R\BG?$[Q9XL'P)\1ZK V@W%VH
MC\F^T?4)#"T1D0%U;9D,"<8]#G/:NTL['QR=+U!ISX6MK^0H+:UM[>5K?:#\
MXE8@,=PX&!Q[UR4?P1O;KP?X^T^2;2M%O/%)B=+/28G%C9O'@A@I )9R/G(
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MQ/"GCCP[X[L6O?#>N:?KMHIVM+I]PLH4^C8/!^M;=#36C"]]4%%%%(84444
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M?[@_E4] 'SE\,?ACJWP_\":'XS\*Z8]OXF-NZ:[H-QE#JT E=@!N^Y.N24/
M.<$<UUFJZ.?B5\09IHK:\M-(UKP)<60N;JW:,PR27"81P1PXY)7V->Q;B3DG
M)H+%NI)[UNZSD^9[F*II*W0\C\*_%H>$O#.GZ'XK\/Z[9>(],MTLY+>QTV2Z
MBN_+4(LD$B J5< 'YB,9P:L^ OA[J.I>&]>O?$,FH>'=3\2:Q)K,MKIMWY4U
MHA4)%"TBYR0BKNQQFO5%E=5P'8#T!IM2ZG\JM<KD[LX'Q-KR> 5TS2=3TO4M
M8\)75K)!<ZMB2\GBER-JS*HW%74M\X'! %>6:;X*OO\ A%]>O/!V@WEIX8TO
M7['6_#^A72&&2?R<FZ\I'^9%D+94-R2IZ9KZ25BIRI(/M0S%FR22?4TXU.5:
M(3A<\DU+Q OQ>\9>#8-%TW4XM*T?4#K&I7NHV3VJQ,L;)';@. 6D+.2=N0 O
M7FJWC#QQIMM\</"T[P:H]OIMIJ%K=SQ:7</''+(8=@W!""#M;D<<5[*TC/\
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M%%%%(L**** "BBB@ HHHH **** "BBB@ HHHH *4,5Z$BDHH **** "BBB@
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M&#PFWQ*\/>%KJ;3=(/AVUO)K>SF8IIUXUR4#1G)V,R $KGL#CFO=_!G@C1_
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M=OIEO9Z39VT.F,SV21Q "W9E*LR>A(8@GODUFZ?\+?!^E:@;^T\-:;!>&87
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MZUE[16L^QI[-WN=%1117.;A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!2U+_ (^-*_Z_
MHOYFNPKC]2_X^-*_Z_HOYFNPI]".H4444@"N4D_Y&;6/]VW_ /07KJZY23_D
M9M8_W;?_ -!>FMF'4L4444BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *;)_JW_ -T_
MRIU-D_U;_P"Z?Y4 16/_ !Y0?[@_E4]4;%+G['!^^C^X/X/:I]ES_P ]H_\
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MXH GHJ#9<_\ /:/_ +XHV7/_ #VC_P"^* )Z*@V7/_/:/_OBC9<_\]H_^^*
M)Z*@V7/_ #VC_P"^*-ES_P ]H_\ OB@">BH-ES_SVC_[XHV7/_/:/_OB@">B
MH-ES_P ]H_\ OBC9<_\ /:/_ +XH GHJ#9<_\]H_^^*-ES_SVC_[XH GHJ#9
M<_\ /:/_ +XHV7/_ #VC_P"^* )Z*@V7/_/:/_OBC9<_\]8_^^* )Z*@V7/_
M #UC_P"^*-ES_P ]8_\ OB@">BH-ES_SVC_[XHV7/_/6/_OB@">BH-ES_P ]
M8_\ OBC9<_\ /:/_ +XH GHJ#9<_\]H_^^*-ES_SVC_[XH GHJ#9<_\ /:/_
M +XHV7/_ #VC_P"^* )Z*@V7/_/:/_OBC9<_\]H_^^* )Z*@V7/_ #VC_P"^
M*-ES_P ]H_\ OB@">BH-ES_SVC_[XHV7/_/:/_OB@">BH-ES_P ]H_\ OBC9
M<_\ /6/_ +XH GHJ#9<_\]H_^^*-ES_SVCQ_N4 3T5!LN?\ GM'_ -\4;+G_
M )ZQ_P#?% $]%0;+G_GK'_WQ1LN?^>L?_?% $.I?\?&E?]?T7\S785Q-\LXN
MM*WR(R_;HL@+@]Z[:GT(ZA1112 *Y23_ )&;6/\ =M__ $%ZZNN4D_Y&;6/]
MVW_]!>FMF'4L4444BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&.>E8OB[Q#K'C?Q5X:UK3+VXL?!VF^([:PMOL[%1K$Q9EED;'6!,%5'1CD]
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !39/]6_\
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M-Q;@;9&  PI(((ZX:O6:*%-Q5D-Q39YA)X5\5_$;Q%HUQXTTW3-'T72#+/\
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M31[PNNKEU(0-$   "0^YANR,5ZW14>T=OP*Y$%%%%9&@4444 %%%% !1110
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MJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUU;W4%E::;(\-P^HS3'$20,C;22>#G&WG->8:Q^SGX[\_P 2Z_I2:>NO67Q
M_P"$NT2UNKC]S?0B!(FBD8#]V6&[!/0@5T'Q7^&_Q#_:(^&MQ:>(/#&B^&M3
MTO5+35-(TNXU#[9'=M#DR17#H JJX) VY(ZFER4;KMUU#FJ6?<]!^&GQS7QM
MXMO?">L^'KOPIXFM[-=1CLKFXAN$N+9FV^8DD3%25;AE/(->1_M5^*IM%^+/
MA6U\9ZSXE\-_"6;3I6FU+PVTD8.H;P%6YEB!=$"<CMGK7<? 7X=7WA_Q3?:K
M??"GP[\/1]D%NEQ8:@+N[F8L"XRHVK'P#USGM6_\4-4^*VD^(O\ BE?">@^,
M_"]Q:>7)8WE]]DN8I\G+,7!1XR"..HP:F/+&K[OY_D]1N\H:GB?Q,\2+X%\(
M_!"^\,^+]<^(^E2>+T:*Y@NA<75_"T<FVW++M$@!P/G].>E>L>'?VHM)DA\<
MQ^+]#U#P/J7@^U2_U*ROV28FVD!,<D;QDAMV,8'?BO,_"'[+_B[POH/PVC:+
M3/M=GX\F\6:O:V,NRVL(I5?,, (^8+E1@8SDUTOQ(_9QUOXE_$#XN//+!8:'
MXK\+V>E65[O#LMS$[/\ /'UV@[?J,UK+V,O=D_G\_P#(A>T6J7R^1T_@K]IJ
M#Q!XFT72=?\ "NH>$4\0027&C75]<P2K<B-/,9'$;DQ/LRVUNP/>LG3?VPM)
MOY-.U5_#.I6W@/4;]=-M/%,LT/EO(TGEI(8 _F+$S_*'(_"N;^$_P1U>UUO3
M+?7?@_X3\-+:6DMO=>(K'4?.ED<Q&/?;1@93=GG>1@$BN9^&_P"S/KW@+^Q_
M#%[\)_"'B&#3;T;/&-S?E#+;"0LLC6^"WG 8''RY&:7)0N_\_7S]/\A\U33^
MOT/0?A+\;O&'BSX__$CPW?>%M6.AZ=?6MI#*\MMY6FKY#,6?#[F\TX8;=V 1
MG%:7QVN)_%GQD^$O@%+B:WL+B\G\0:@(6*F6.T4&*,D?PF1U)_W:/!?@GQWX
M"_:*\=ZG!HECJ/@[Q?<6MY)JQOA'-9F*#RS'Y.,N2<<CCFD^.\,OA#XR?"7Q
M^()I].M[R?P_J!A4L88[M0(I"!_")$ )[;JCW?:+E[?C;_,K7D=^_P"IYA\&
M?C%XG\+_ +2GCK3/$^HW%]X(\1^*KS1]'FN)"RZ=?P@,MN,_=61&^4>JU'\0
M?C%XF\9_M7^ [;P_J5Q9?#[1O$1T"[-O*534[\PM)*IQPR1 !?\ >)KT&P_9
MHN/%G@_XL>'/%#_V8GB+Q7<ZWI&HV,H>>USL,%PO]UU93Q^'>I+[]F^X\*V_
MP4TCPJBW>F^$M=;4=5O+N4)-/NBD$DY_ONTCY(]_:M>>ES7ZVMY;;_H9\M2U
MNG_!-SQY^TE<_#S6YFU7X?\ B"#PA;:A%IUQXFD\I(E>1@BR)$6WO%N8#>!C
MFG77[2,EQ\7-4^'^A>"=8UZ_TFYM4U&^MWC2UM;>9%83L['MD_*.3M)KPKXD
M_LZ_%?XA1^*;+5M)CUS5I]96\T_Q%=>(72UCLEG1XX(K-2%5P@()<$'&<U]
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M5]<\(^(?@SX^^$D%E\0?$'B?X@:]JZ1:Y975ZTUI>66TM=3"W/$,<?&T@#'
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M9SA41!RQZGV )[4.$D[-!S)J]SH**13D XQ2U!04444 %%%% !1110 4444
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M)^S1W5_=RW4D,/7RXS(QV+P.!Z4W4BW?^MA*#6AYM<-\1O\ A>L( \,?:_[
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M?[2ZLZJ>>F!],5VFD^&--T/4-5OK*W\FZU29;B[?<3YCA0H.">. !Q65XO\
MAIH7C:_LK_48KB+4+-7CAO+&ZDMIA&^-T9>-@2IP/E/%-U%)Z]A<K2/%]9\0
M:[JVC+:VWB/4+![KXCR:6;NTE'F):[V!B4G( P,>U3>,M:U7X,7WCJTT35KZ
M[M5\-KJEO'J<YN/LMSY_E-(I;G!#AB.F5KUO2_A'X3T73++3['28[:SL]2_M
M>"&-WPMUR?,Z\G))P>.:U=0\$Z+JVJ7>H7MA'=7-U8MIL_FY99+<MN,97I@G
MVJ_:QOMH+D=O,\2\1> 8?!_C[X03IX@U;5KB?5)?M#:A>&9;IS:N3+M/ /\
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M6/\ WZ;_ !H\G7O^?JQ_[]-_C1;S VJ*Q?)U[_GZL?\ OTW^-'DZ]_S]6/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.1.u2</span><table class="report" border="0" cellspacing="2" id="idm139671597447488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 10, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 10,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KIORA PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0443284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">332 Encinitas Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Encinitas<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">224-9600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KPRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001372514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MPNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    "  S.*I8!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M #,XJEB1V71D[P   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( #,XJEB97)PC$ 8  )PG   3
M  "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ,SBJ6"%M
MQJ56!   &!$  !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( #,XJEB?H!OPL0(  .(,   -
M  "  9H,  !X;"]S='EL97,N>&UL4$L! A0#%     @ ,SBJ6)>*NQS
M$P(   L              ( !=@\  %]R96QS+RYR96QS4$L! A0#%     @
M,SBJ6*K$(A8S 0  (@(   \              ( !7Q   'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( #,XJE@D'INBK0   /@!   :              "
M ;\1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( #,X
MJEAED'F2&0$  ,\#   3              "  :02  !;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     )  D /@(  .X3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.1.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="kprx-20240510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="kprx-20240510.htm">kprx-20240510.htm</File>
    <File>kprx-20240510.xsd</File>
    <File>kprx-20240510_lab.xml</File>
    <File>kprx-20240510_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "kprx-20240510.htm": {
   "nsprefix": "kprx",
   "nsuri": "http://www.eyegatepharma.com/20240510",
   "dts": {
    "inline": {
     "local": [
      "kprx-20240510.htm"
     ]
    },
    "schema": {
     "local": [
      "kprx-20240510.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "kprx-20240510_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "kprx-20240510_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://www.eyegatepharma.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20240510.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "kprx-20240510.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001372514-24-000054-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001372514-24-000054-xbrl.zip
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M$K((7CV4=AL0LT>[@"9!2)+_+CO5 Y5%[5B(&P0T,DI.]&BX;%B_![8<D*=
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M(@AI,AB1HZL_KW]&RD.XX@3S? *$G#']6,^PA#H#0<@1"RF/JIER?151RX>
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MJ8V10TR'OU9Y5ACV_V#857V2>JBR)!:B3)N*[?O!.%]K86J1?,B2*7S9G3!
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M1<F*9/&BR\\E8:(@>@!Y4OD:!'?(K3?("")]>&\7NICR;M#24(F(\7B1,I*
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M7TT>^0Y_]@0_.A[E0\0OB'6 D5+? $V!SH3>*:66O5-"$M\(3XR[MR'C2O-
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M#P"S,F>TWNH,\FR7XQ6RX?RN5/M!)JITH'\@\655_J\*XK]B:/\'4$L#!!0
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M;4_N(7\A4E+3KCZ>=RCK55IO'!3L-RP8K]C^^=$:.L-^M]>3/U!+ P04
M"  S.*I8P[Y7!$,*   46   %0   &MP<G@M,C R-# U,3!?;&%B+GAM;,V<
M76_;.!:&[_LKM-F;76!8B^*'R*+MH)MI%\5FVJ)),8-=+ Q^*1'J2(&L-,F_
M7TJV4SN6;)*RE;V8J>/0YSWO"1^3AY+]^M?[ZUGTPU3SO"S>G,"7\4ED"E7J
MO+A\<_+MX@-@)[^^??'B]5\ ^/,?7\^BWTIU>VV*.CJMC*B-CN[R^BJJKTST
M1UE]SW^(Z,M,U%E970/PMGW9:7GS4.675W64Q E>#5O]MGJ%*$F4D H@)BG
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M/VYJL%&]K"JOW>S4I=L?<%$V*WH2E94VE=U3=ACHG$8PD1=Y/3-3B$R"(4L
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MJ%U8E (RDS'52J929JZ@..@=&9]%!M%&"K]$;1*V:M$RD:C)Q)TMES+N)^[
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MPOC][8O5,_GB2V3?OO@?4$L#!!0    ( #,XJE@JJ*CTW08   (S   5
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MZ "VQ=&VWWE1!]?VK/^E7;-G1W1;Y'$8Z781QHE@A[?;.#\YF,WNZ6CJ$CY
MFG7?OWXXWX&$.UBB)S<KUZS=8:C7BV[4XJQ&5:"]_?GMW0:.Y]MBO2GA<=^J
M@70\_[1I;DGG6)HQVJ'^\_[$Q9_@FP:VJ)A^LA>XX^'\#N6%AL!M"U6$^QD^
MPI1UV!E4=OS6?YQ9.@]EOS>/4.3]54_]MFU<:'.C&!,B&9)8DD0FC[J*U!'%
M8R8REWEP<G?>G=U;-+QWQQ;"X;+^O, +HUNXZ'YTI(B>D"=P]^2\S.['^^\*
MQ^9*RPRBM21E@1%)HR>&,[PQ&#.1)Z^DXJ/,_A)MU^HOG7K:A%G=1&AP 7F$
M<TUXXN!=Z3Z,6&Q<@Q<B8564\?'LU-3K??BJK?? W+U;T-SY#&>=H&D@7MQ[
MY=G)]3-K<5F%?N0^/'X)35''MU7\$6^27. ,J*"<9(9%(J.(Q//D"&<AZB2U
M4]'MQ?4[L(,TP*>O@9=S^<IB>%NU17OW 99%QT35_N+6D#.:(H!.Q'OJB;26
M$>=90EZ @XS,A6A':>%;J(.D(*8KA=%,3D()YYBK-9NZZ8G_B/S#67U=M<W=
M61TAEY R )R$\;C42:8I\488 M*Y*(1T=&18&V#$()W(J>MD?SQ/0C97[O8\
M(GU%*NZ3T%^NUQZ:7%'.,Z$8L0R70TD5Q["8&-$*J(; N II#X)Y!GZ05+*I
M2V4?W$Y").^*$AYL=TQX9J,E&>48(3,3<5T,GN@8A,YPF929VH,N_D0<) 4U
M=2F\D,%)>/\T1F1]^_"%=1NP7&B<O 1!E.18JG/)"2YXR$MTR4JAC/;CDLYG
MH0?I04]=#V,YG:@P> X:/"B4L[(R$&FT)E9WF\$'Q8,+U(\K1)^%'B0,\_T)
MX^]Q.B5AG.'/]\U5?5/E+F5<,B.(C0*K;' !@Y\WQ OOG<JH5G$?8>,)\"!1
MV.]$%"_D<TJ2Z!/F]\UE4W\NJ@ YQKPL</"$@J%$ZBP1 ]$0AWPX09V"#/:G
MBZ_0A_6QZ'>BCC'43DDBE_6V=>5_BTU?4'F:>2^"((*!(=('G("G ?EAWGHE
MF)%^?P+9P1XFCPGW.?=$ZRN+HUOU3AMPO=V*!1$M#P24PW7/9I@C.9](I"FR
M+!KC3!C7GO\";9@ )MSD?#%UK^SR[H%8>;FJJ\>:246G#:2,,(=9L?02B).1
M$YVT\M(D;=.X]M77B,-</^&FYB@*7]G]OS5%VT)U5J_7U]5#ZV2;&TH-ICV.
M!$DS(D.4Q&)=1)PPP6JN0?MQM_XW88<)8<)=R_%DOK(:/M9E$8JVJ)8_8X+3
M%*[,G>7:B62)UP:MER80A_,A- DN-"AM^+CNPU/,83J8<$MR)(VO+(++!CH%
M R:V_9/;[J%_\SZA';EDFJG@,@(VP^K8>4LL>$DBUPP#F^9)T5%B>!Y[F"@F
MW)S<$ZW3$L?Y=GL-S<Y<5/0Q8>Q+X+$4LBP2HX0EU#FLEP-3*L1]2N2)!<.$
M,N&NY5XI?NV  N$:@^(=X_ZJ:$O(,QX3R[@E@DK;/8\!8CS#_,AKJQ(61-*+
M<>'D*\1A<IAPKW(4A:_L_JO&=>\T?KQ;^[K,!98_U&:2",LQ!BIEB8M8"&M,
ME[ECQF=\7+]Z!VZ8XR?<CWPY>1.YZ=_>AI6KEM"_Y.'!),\QQ@F514R O"%&
M,$U4"M%PJC,7QW4?OX4Z[,VI"7<=1U,YB6[CVS4T2Y3R?YKZIEUA<-NXZB[G
M7D?FC.B:IMTKR%@7&8>S"GA ,Q:=D^-"P?\!'R:,R?<;QQ,["7V<(66-*\\Q
MQ;G]">YR*23:B+F-RY@G$F0@1JI$> ;&6R43,K0'97P%.TP3$VY!CB?SE=5P
MBOEN['+>=Z5;Y@ B4U1&PH,V6!5)2:QUB@2M,!8FP[U@HU2P S?,^Q/N0KZ<
MO+UY_<WB"7D7N./DX.% ]]']9>+DX']02P$"% ,4    "  S.*I8XFT>[(P?
M  !"5 $ '@              @ $     97@Y.3$M<')E<W-R96QE87-E;6%R
M8V@S,3(N:'1M4$L! A0#%     @ ,SBJ6"6]:*MY#P  F60  !$
M     ( !R!\  &MP<G@M,C R-# U,3 N:'1M4$L! A0#%     @ ,SBJ6)9C
M(N!R @  ?P<  !$              ( !<"\  &MP<G@M,C R-# U,3 N>'-D
M4$L! A0#%     @ ,SBJ6,.^5P1#"@  %%@  !4              ( !$3(
M &MP<G@M,C R-# U,3!?;&%B+GAM;%!+ 0(4 Q0    ( #,XJE@JJ*CTW08
M  (S   5              "  8<\  !K<')X+3(P,C0P-3$P7W!R92YX;6Q0
52P4&      4 !0!0 0  ET,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>kprx-20240510_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="kprx-20240510.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2024-05-10</startDate>
            <endDate>2024-05-10</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001372514</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-05-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">KIORA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36672</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">98-0443284</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">332 Encinitas Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 102</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Encinitas</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">92024</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">224-9600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">KPRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
